Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 1987, Abingworth is a life science investment firm with offices in London, New York, and San Francisco. The firm manages over $1 billion in assets and has invested in more than 100 companies in the biotech and healthcare sectors. Its team combines extensive industry experience with a strong track record of successful exits.
Abingworth invests in private and public companies across seed, early stage, and development stages, focusing on biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, and cell therapies. Investment sizes typically range from $15 million to $30 million for seed and early-stage companies, with a minimum of $30 million for development-stage investments. The firm supports its portfolio companies for a holding period of 2 to 10 years.
Abingworth has backed over 100 life science companies, achieving 36 product approvals since 2012, along with 75 IPOs and 52 mergers and acquisitions. Notable companies include Median Technologies, known for its AI-based lung cancer screening device, and Jasper Therapeutics, which is focused on clinical growth.
Submit your pitch through their form at https://abingworth.com.
Yes, Abingworth often leads investment rounds, particularly in seed and early-stage funding for biopharma companies.
Abingworth typically participates in follow-on investments to support the growth of its portfolio companies, especially during critical development stages.
Abingworth manages over $1 billion in assets, allowing for significant investments in the life sciences sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.